Drugs for exceptionally rare diseases: Do they deserve special status for funding?

QJM: An International Journal of Medicine

Volumn 98, Issue 11, 2005, Pages 829-836

  Hughes, D A ^a   Tunnage, B ^a   Yeo, S T ^a  

^a BANGOR UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG LEGISLATION; DRUG RESEARCH; DRUG SAFETY; EUROPEAN UNION; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH CARE POLICY; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RARE DISEASE; REIMBURSEMENT; RESOURCE ALLOCATION; RISK MANAGEMENT; TAX; UNITED KINGDOM;

EID: 27744461277     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hci128     Document Type: Article

References (24)

1. Lang J, Wood SC. Development of orphan vaccines: An industry perspective. Emerg Infect Dis 1999; 5:749-56.
2. National Institute for Clinical Excellence. NICE Citizens Council Report Ultra Orphan Drugs. London, NICE, 2004.
3. European Parliament and the Council of the European Union. Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities 2000; L18:1-5.
4. The European Agency for the Evaluation of Medicinal Products. Report on the first 3-year mandate of the committee for orphan medicinal products (COMP). 2003.
5. Scottish Medicines Consortium. Laronidase: Summary of recommendations. 2004.
6. Thames Valley Priorities Committees. Policy Statement 71 Laronidase (Aldurazyme) for Mucopolysaccharidosis type 1 (MPS1). Thames Valley, 2004.
7. Welsh Medicines Partnership. Therapeutic Development Assessment Aldurazyme® AWMSG/1204. 2004
8. Lagakos SW. Clinical trials and rare diseases. N Engl J Med 2003; 348:2455-6.
9. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal, NICE 2004. [http://www.nice.org.uk/pdf/ TAP_Methods.pdf]
10. National Institute for Clinical Excellence. NHS should consider paying premium prices for drugs to treat patients with very rare diseases says NICE Citizen's Council. NICE, 2005.
11. Den Exter A, Hermans H. The right to health care: A changing concept? In: Den Exter A, Hermans H, eds. The Right to Health Care in Several European Countries. The Hague, Kluwer Law International, 1999:1-10.
12. Gericke CA, Riesberg A, Busse R. Ethical issues in funding orphan drug research and development. J Med Ethics 2005; 31:164-8.
13. McKie J, Richardson J. The rule of rescue. Soc Sci Med 2003; 56:2407-19.
14. Hadorn DC. Setting health care priorities in Oregon. Cost-effectiveness meets the rule of rescue. JAMA 1991; 265:2218-25.
15. Dolan P, Shaw R, Tsuchiya A, Williams A. QALY maximisation and people's preferences: A methodological review of the literature. Health Econ 2005; 14:197-208.
16. Williams A. Intergenerational equity: An exploration of the 'fair innings' argument. Health Econ 1997; 6:117-32.
17. Chapman S, Reeve E, Rajaratnam G, Neary R. Setting up an outcomes guarantee for pharmaceuticals: New approach to risk sharing in primary care. Br Med J 2003; 326:707-9.
18. Department of Health. Cost effective provision of disease modifying therapies for people with multiple sclerosis. London, DoH, 2002.
19. Sudlow CL, Counsell CE. Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. Br Med J 2003; 326:388-92.
20. Møldrup C. No cure, no pay. Br Med J 2005; 330:1262-4.
21. Clarke JTR, Amato D, Deber RB. Managing public payment for high-cost, high-benefit treatment: Enzyme replacement therapy for Gaucher's disease in Ontario. CMAJ 2001; 165:595-6.
22. Williams A. What Could be Nicer Than NICE? London, Office for Health Economics, 2004.
23. Department of Health. National designation and funding of the service for patients with lysosomal storage disorders. 2004.
24. Light DW, Walley T. A framework for containing costs fairly. In: Mossialos E, Mrazek M, Walley T, eds. Regulating Pharmaceuticals in Europe: Striving for efficiency, equity and quality. Cornwall, Open University Press, 2004.